Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pharmaust Limited ( (AU:NUZ) ) has shared an update.
Neurizon Therapeutics Limited announced positive results from the Open-Label Extension (OLE) study of its lead candidate, NUZ-001, for treating ALS. The study confirmed the long-term safety and efficacy of NUZ-001, showing significant survival benefits and a reduction in the rate of functional and respiratory decline compared to historical controls. These findings support the potential of NUZ-001 as a disease-modifying therapy for ALS, reinforcing its advancement into further clinical trials, including the upcoming HEALEY ALS Platform Trial.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.50 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
More about Pharmaust Limited
Neurizon Therapeutics Limited is a clinical-stage biotech company focused on developing innovative treatments for neurodegenerative diseases. The company is dedicated to advancing therapies that address unmet medical needs, particularly in the area of motor neurone diseases such as amyotrophic lateral sclerosis (ALS).
Average Trading Volume: 345,618
Technical Sentiment Signal: Buy
Current Market Cap: A$73.85M
For a thorough assessment of NUZ stock, go to TipRanks’ Stock Analysis page.